CCC
JAZZ icon

Crescent Capital Consulting’s Jazz Pharmaceuticals JAZZ Stock Holding History

Crescent Capital Consulting’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2K Hold
16
– – ﹤0.01% 475
2021
Q3 		$2K Hold
16
– – ﹤0.01% 514
2021
Q2 		$3K Buy
+16
New +$2.77K ﹤0.01% 432

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Crescent Capital Consulting's JAZZ Position: Q4 2021 in Review

Crescent Capital Consulting held its Jazz Pharmaceuticals (JAZZ) position steady in Q4 2021 at 16 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

Crescent Capital Consulting first reported a position in JAZZ in Q2 2021 and has held it in 3 quarters since. The position peaked at $3K in Q2 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

  • Crescent Capital Consulting held 16 shares of Jazz Pharmaceuticals worth $2K as of Q4 2021.
  • Crescent Capital Consulting left its Jazz Pharmaceuticals share count unchanged in Q4 2021.
  • Jazz Pharmaceuticals made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #475 holding.
  • Crescent Capital Consulting first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 3 quarters since.
  • Crescent Capital Consulting's Jazz Pharmaceuticals position peaked at $3K in Q2 2021.
  • 454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.